Immix Biopharma (IMMX) Short Interest Ratio & Short Volume $1.59 +0.01 (+0.89%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immix Biopharma Short Interest DataImmix Biopharma (IMMX) has a short interest of 367,400 shares, representing 2.24% of the float (the number of shares available for trading by the public). This marks a -4.89% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.1, indicating that it would take 4.1 days of the average trading volume of 131,376 shares to cover all short positions.Current Short Interest367,400 sharesPrevious Short Interest386,300 sharesChange Vs. Previous Month-4.89%Dollar Volume Sold Short$606,210.00Short Interest Ratio4.1 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares27,722,000 sharesFloat Size16,380,000 sharesShort Percent of Float2.24%Today's Trading Volume6,477 sharesAverage Trading Volume131,376 sharesToday's Volume Vs. Average5% Short Selling Immix Biopharma? Sign up to receive the latest short interest report for Immix Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMMX Short Interest Over TimeIMMX Days to Cover Over TimeIMMX Percentage of Float Shorted Over Time Remove Ads Immix Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025367,400 shares $606,210.00 -4.9%2.2%4.1 $1.65 2/28/2025386,300 shares $687,614.00 -0.8%2.4%3.3 $1.78 2/15/2025389,400 shares $771,012.00 +16.1%2.4%2.4 $1.98 1/31/2025335,300 shares $650,482.00 -11.5%2.1%2.1 $1.94 1/15/2025378,900 shares $765,378.00 +6.3%2.3%2.4 $2.02 12/31/2024356,500 shares $784,300.00 -11.0%2.2%2.2 $2.20 12/15/2024400,500 shares $817,020.00 -14.9%2.4%2.3 $2.04 11/30/2024470,700 shares $993,177.00 +17.5%2.9%3 $2.11 11/15/2024400,700 shares $637,113.00 -7.9%2.5%3.2 $1.59 10/31/2024434,900 shares $695,840.00 -3.5%2.7%3.9 $1.60 Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 10/15/2024450,500 shares $662,235.00 -18.5%2.8%3.2 $1.47 9/30/2024552,800 shares $823,672.00 +15.2%3.4%3.8 $1.49 9/15/2024479,700 shares $892,242.00 +48.1%2.9%3.2 $1.86 8/31/2024324,000 shares $693,360.00 -43.0%2.0%2.1 $2.14 8/15/2024568,400 shares $1.07 million -1.7%3.6%3.6 $1.89 7/31/2024578,200 shares $1.20 million -7.5%3.8%3.6 $2.07 7/15/2024625,300 shares $1.28 million +12.2%4.1%4.5 $2.04 6/30/2024557,400 shares $1.10 million +17.8%3.6%3.8 $1.98 6/15/2024473,100 shares $974,586.00 +39.7%3.1%3.6 $2.06 5/31/2024338,700 shares $714,657.00 -7.6%2.2%2.5 $2.11 5/15/2024366,500 shares $861,275.00 -5.4%2.4%2.3 $2.35 4/30/2024387,500 shares $840,875.00 +10.8%2.8%1.9 $2.17 4/15/2024349,900 shares $930,734.00 -10.0%2.5%1.3 $2.66 3/31/2024388,800 shares $1.19 million +22.8%2.8%1.4 $3.07 3/15/2024316,600 shares $835,824.00 +19.9%3.1%1.1 $2.64 2/29/2024264,100 shares $884,735.00 -14.5%3.5%0.7 $3.35 2/15/2024308,900 shares $898,899.00 -37.0%4.1%0.9 $2.91 1/31/2024489,900 shares $1.87 million +123.2%6.4%1.4 $3.82 1/15/2024219,500 shares $1.28 million +3.1%2.9%0.8 $5.81 12/31/2023212,900 shares $1.47 million +52.3%2.8%0.8 $6.92 12/15/2023139,800 shares $1.02 million +0.1%1.8%0.5 $7.27 11/30/2023139,700 shares $713,867.00 -42.4%1.9%0.6 $5.11 11/15/2023242,600 shares $1.08 million -17.8%3.2%1.1 $4.46 10/31/2023295,000 shares $1.07 million +71.3%3.9%1.4 $3.62 10/15/2023172,200 shares $514,017.00 +71.7%2.3%0.9 $2.99 9/30/2023100,300 shares $343,026.00 +39.5%2.0%0.5 $3.42 9/15/202371,900 shares $191,973.00 -33.4%1.7%0.5 $2.67 8/31/2023107,900 shares $219,037.00 +65.0%2.5%0.8 $2.03 8/15/202365,400 shares $121,644.00 +10.3%0.9%0.4 $1.86 7/31/202359,300 shares $122,158.00 +8.2%1.0%0.2 $2.06Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse (Ad)Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.Go Here to Learn What's Happening and How to Prepare >> 7/15/202354,800 shares $125,492.00 -45.0%0.9%0.2 $2.29 6/30/202399,600 shares $267,924.00 -46.1%1.7%0.3 $2.69 6/15/2023184,700 shares $435,892.00 -16.2%3.1%0.6 $2.36 5/31/2023220,300 shares $445,006.00 +43.8%4.2%0.7 $2.02 5/15/2023153,200 shares $315,592.00 -30.8%2.9%0.5 $2.06 4/30/2023221,300 shares $546,611.00 +86.8%4.0%1.1 $2.47 4/15/2023118,500 shares $213,501.45 -23.1%2.1%1.2 $1.80 3/31/2023154,100 shares $280,462.00 +5.2%2.8%1.4 $1.82 3/15/2023146,500 shares $276,885.00 +24.3%2.5%0.8 $1.89 2/28/2023117,900 shares $245,232.00 +20.7%2.0%0.1 $2.08 2/15/202397,700 shares $225,687.00 -43.0%1.7%0.1 $2.31 1/31/2023171,400 shares $445,640.00 -0.9%2.9%0.1 $2.60 1/15/2023172,900 shares $380,380.00 -19.2%2.9%0.2 $2.20 12/30/2022214,100 shares $490,289.00 +128.3%3.6%0.2 $2.29 12/15/202293,800 shares $184,786.00 +281.3%1.6%0.1 $1.97 11/30/202224,600 shares $29,766.00 +5.1%0.4%0.5 $1.21 11/15/202223,400 shares $24,804.00 -20.1%0.4%0.4 $1.06 10/31/202229,300 shares $29,300.00 +8.1%0.5%0.6 $1.00 10/15/202227,100 shares $32,791.00 +11.1%0.5%0.7 $1.21 9/30/202224,400 shares $33,184.00 -60.5%0.4%0.5 $1.36 9/15/202261,700 shares $106,741.00 +92.8%1.1%0.6 $1.73 8/31/202232,000 shares $58,240.00 +111.9%0.6%0.2 $1.82 8/15/202215,100 shares $35,334.00 -74.5%0.3%0 $2.34 7/31/202259,300 shares $144,692.00 -46.5%1.0%0 $2.44 7/15/2022110,900 shares $302,757.00 No Change1.9%0 $2.73 IMMX Short Interest - Frequently Asked Questions What is Immix Biopharma's current short interest? Short interest is the volume of Immix Biopharma shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 367,400 shares of IMMX short. 2.24% of Immix Biopharma's shares are currently sold short. Learn More on Immix Biopharma's current short interest. What is a good short interest ratio for Immix Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMMX shares currently have a short interest ratio of 4.0. Learn More on Immix Biopharma's short interest ratio. Which institutional investors are shorting Immix Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immix Biopharma: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immix Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.24% of Immix Biopharma's floating shares are currently sold short. Is Immix Biopharma's short interest increasing or decreasing? Immix Biopharma saw a drop in short interest in March. As of March 15th, there was short interest totaling 367,400 shares, a drop of 4.9% from the previous total of 386,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immix Biopharma's float size? Immix Biopharma currently has issued a total of 27,722,000 shares. Some of Immix Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immix Biopharma currently has a public float of 16,380,000 shares. How does Immix Biopharma's short interest compare to its competitors? 2.24% of Immix Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immix Biopharma: Amarin Co. plc (2.69%), LifeVantage Co. (15.90%), biote Corp. (2.38%), Contineum Therapeutics, Inc. (5.87%), Rezolute, Inc. (4.41%), Neurogene Inc. (12.59%), Genfit S.A. (0.11%), Nanobiotix S.A. (0.02%), MediWound Ltd. (12.02%), Molecular Partners AG (0.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Immix Biopharma stock? Short selling IMMX is an investing strategy that aims to generate trading profit from Immix Biopharma as its price is falling. IMMX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immix Biopharma? A short squeeze for Immix Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMMX, which in turn drives the price of the stock up even further. How often is Immix Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMMX, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies AMRN Short Interest LFVN Short Interest BTMD Short Interest CTNM Short Interest RZLT Short Interest NGNE Short Interest GNFT Short Interest NBTX Short Interest MDWD Short Interest MOLN Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMMX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.